Related Experiment Video
Updated: May 16, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
[Chemoradiotherapy for advanced gastric cancer]
Tsunehiro Takahashi1, Yoshiro Saikawa, Kazumasa Fukuda
1Keio Cancer Center, Keio University, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 14, 2012
Summary
Chemoradiotherapy is standard for many cancers in the US and Europe but not yet in Japan. Advances in radiation technology may enable its use for advanced gastric cancer.
Area of Science:
- Oncology
- Radiation Oncology
Context:
- Chemoradiotherapy is a standard treatment for various cancers in the US and Europe, including gastric cancer, often used as adjuvant therapy.
- In Japan, chemoradiotherapy for gastric cancer is not standard, with limited indications and use primarily for palliative care.
- Challenges in gastric cancer radiation include targeting accuracy due to peristalsis, risks of perforation/ulceration, and low radiosensitivity of adenocarcinoma.
Purpose:
- To describe the current status of chemoradiotherapy for gastric cancer in Japan and internationally.
- To outline a specific approach to managing locally advanced gastric cancer.
Summary:
- While established in Western countries, chemoradiotherapy for gastric cancer faces challenges in Japan, including limited application and specific technical difficulties.
- Recent technological advancements in radiation therapy offer potential for improved precision in treating gastric lesions and lymph nodes.
- The report reviews global and Japanese perspectives on gastric cancer chemoradiotherapy and presents a novel approach for locally advanced cases.
Impact:
- Highlights the disparity in gastric cancer treatment standards between Japan and Western countries.
- Suggests that technological advancements may overcome previous limitations of radiation therapy for gastric cancer.
- Provides insights into a multidisciplinary approach for locally advanced gastric cancer, potentially improving patient outcomes.
More Related Videos
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...